

Date:

February 1, 2023

To:

The Honorable Senator Patterson Senate Health Care Committee

From:

Steve Elfrink Co-Founder OmTerra Corporation

RE: SB 303

My name is Steve Elfrink and I am an Oregon resident living in Grants Pass. I want to take this opportunity to publicly state my support for SB303. I am the co-founder of a psychedelic services corporation and currently enrolled in an OHA approved / HECC certified psilocybin training program. I am also in the process of going through the steps necessary to open a licensed psilocybin center in Grants Pass. Our scope of care will be broad; providing care for clients with PTSD, depression, anxiety and addiction. Part of our mission is to create a non-profit to raise funds for scholarships to provide services to Vets and the underserved population.

For 30 years, I worked in the corporate sector of the medical device field - primarily in ophthalmology. During that time, I was involved with many new, novel and, sometimes controversial medical devices and surgical procedures. The most controversial among them was the surgical procedure, LASIK, for the correction of myopia.

Through the process of bringing new surgical procedures to market, I learned the importance of data collection as a way to validate safety and efficacy. As Peter Drucker famously stated, "if you can't measure it, you can't manage it." What allowed LASIK to become the highly successful and safe procedure we know it as today was the amount of data that was collected and ultimately shared with the FDA. It was this process that led to the federal approval for the procedure. Data collection led to the understanding of what was working, and where improvement was needed.

The wide-scale rollout of psilocybin services that is underway in Oregon is a brand new, trailblazing endeavor. It has not been attempted elsewhere in the US, nor anywhere in the world. We are the first. With the weight and seriousness of this "first to market" program,



there is an inherent need to be able to measure outcomes. The need for a mechanism for data collection is paramount for the success of this program. There are many reasons for this.

First of all, there is the need to monitor adverse outcomes. Like any medication or treatment modality, psilocybin therapy will have adverse reactions. This is not something to be frightened of. It is something that needs to be monitored and documented. The goal here is to be proactive vs. reactive as adverse reactions appear. Are they tied to specific dosing? To a specific service center? Are there adverse reactions with a subset of clients with specific presenting behavioral health conditions?

With the launch of any program that has the immensity and far-reaching implications of the Oregon Psilocybin Program, it is extremely important to be several steps ahead of understanding where possible issues may arise. This will provide the opportunity for course correction to minimize further possible adverse reactions and improve patient outcomes.

The benefit of the data collection is that it also provides markers of the successes of the program. This includes the number of people who had a positive outcome, a better understanding of what behavioral health conditions are showing the greatest demand and effective dosing ranges - just to name a few. Oregon needs to be able to show to the world that this program can work. The way to do that is through data collection. The proof is in the numbers.

Data collection will show who is getting services, and conversely, who it is not reaching. Without data collection, we won't know if the diverse communities of Oregon are being fairly represented, whether there are some people who are not able to access services that should be universally available. This is critical data to understand and course correct as needed to make the necessary changes to ensure these communities have access.

For me, data collection is just simple common sense. A necessary endeavor that will ensure the best possible outcomes for clients seeking psilocybin services. My personal, ultimate goal is to be able to provide my clients with the highest quality care. I will gladly share the data from my psilocybin service center to help improve the state-of-the-art of this very promising and much needed healing modality. This is where the common good of the collective can help usher in a new era of safe and efficacious psilocybin services.

Steve Elfrink